The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Suddenly 2020’s medtech M&A landscape looks very different.
Batch testing could allow large numbers of people to be ruled out as having Covid-19, but accuracy concerns remain.
The pandemic prompts only a slight drop in medtech approvals.
Medtechs going public in 2020 raised a decent amount of cash, but have had a turbulent time of it since.
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
2019 was an average year for medtech M&A. 2020, not so much.
Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.